RxDoctor Payments Data

Amit Nanavati, MD

Interventional Cardiology · Palm Coast, FLNPI 1932373479

Payments from drug & device makers

$17,382in general payments, 2019–2025

Across 459 payments — averaging $37.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Penumbra, Inc.$1K
  • Johnson & Johnson$734
  • E.r. Squibb & Sons, L.L.C.$651
  • Novartis$620
  • Amgen$530
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$8,78451%
  • Food & beverage$8,51949%
  • Education$600%
  • Entertainment$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,382 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,729,459
Medicare patients
2,603
Services billed
16,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban786$965,752
XareltoRivaroxaban376$503,361
EntrestoSacubitril/Valsartan191$222,178
JardianceEmpagliflozin41$55,438
MultaqDronedarone Hcl28$44,659
BrilintaTicagrelor36$43,847
Repatha SyringeEvolocumab22$31,200
Ranolazine ErRanolazine201$19,443
Praluent PenAlirocumab23$18,377
NexlizetBempedoic Acid/Ezetimibe13$12,755
Dabigatran EtexilateDabigatran Etexilate Mesylate28$11,016
Metoprolol Succinate600$7,962
Atorvastatin Calcium637$7,043
NexletolBempedoic Acid12$6,352
Amiodarone Hcl190$4,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$965,752786 claims
Johnson & JohnsonXarelto$734$503,361376 claims
NovartisEntresto$620$222,178191 claims
Boehringer IngelheimJardiance$312$55,43841 claims
Sanofi-aventis U.S. LLCMultaq$56$44,65928 claims
AstraZenecaBrilinta$61$43,84736 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$351$19,10725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Palm Coast

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →